ChristianaCare Adds Prescription Digital Therapeutics for Treatment of Substance Use Disorders | Pear Therapeutics
Earlier this year Pear announced its FDA-authorized digital therapeutics, reSET and reSET-O, were added to PreferredOne’s list of covered standard healthcare benefits for all its members (more than 364,000). In September, Pear announced a collaboration with Wellpath Community Care Centers to elevate the nation’s battle against the substance and opioid use crisis.
Delaware-based health system ChristianaCare is expanding its innovative work to transform care through data and technology by adding Pear’s prescription digital therapeutics (PDTs or DTx) to treat substance use disorder and opioid use disorder. ChristianaCare will provide patients access to Pear Therapeutics Inc.’s reSET and reSET-O PDTs through Project Recovery, ChristianaCare’s outpatient program for people with substance-use disorders.
Advancements in and the increasingly dominant role of mobile technology and artificial intelligence (AI) in our daily lives have broadened the capacity of PDT’s in healthcare. PDTs are a new therapeutic group that uses software to treat the disease directly. Unlike traditional medicines, PDTs are intended to collect real-world data for use by prescribing clinicians and population health management by payers and health systems. Digital therapeutics undergo clinical trials, collect real-world outcomes, and are based on patient-centered core principles and product development best practices – including product design, usability, data security, and privacy standards.
Pear is excited to team with ChristianaCare to integrate our PDTs into their treatment paradigm for suitable patients who are fighting the battle of opioid or substance use disorder. We believe these innovative therapies can benefit ChristianaCare patients.Julia Strandberg, chief commercial officer of Pear Therapeutics
Delaware’s Opioid Crisis
In 2018, Delaware providers wrote 60.6 opioid prescriptions for every 100 persons compared to the average U.S. rate of 51.4 prescriptions. And according to the Centers for Disease Control and Prevention(CDC), Delaware has the second-highest rate of overdose deaths in the nation. Substance and opioid use disorders are chronic, treatable diseases. Staying in treatment is critical for people on their recovery journey. reSET and reSET-O will give patients a discreet, 24/7 evidence-based tool to complement their remote or in-office addiction therapy provided by their care team.
The COVID-19 pandemic has highlighted the vital importance of connecting people with substance-use disorder to effective therapies, and ensuring that they have access to these therapies when and where they need it. FDA-authorized prescription digital therapeutics used with complementary therapy are shown to keep patients on the path to recovery. The use of proven software-based therapeutics could provide innovative, convenient and cost-effective care to assist in the fight against addiction.Jolomi Ikomi, M.D., Medical Director of Project Recovery at ChristianaCare
What is Pear Therapeutics reSET?
reSET, the first Prescription Digital Therapeutic (DTx) to receive authorization from FDA to improve disease outcomes, is a 90-day DTx for Substance Use Disorder (SUD) intended to provide cognitive behavioral therapy (CBT), as an adjunct to a contingency management system, for patients 18 years of age and older who are currently enrolled in outpatient treatment under the supervision of a clinician.
What is reSET-O?
reSET-O, the first PDT to receive Breakthrough Designation and authorized by FDA in December 2018, is an 84-day DTx for Opioid Use Disorder (OUD) intended to increase retention of patients in outpatient treatment by providing cognitive behavioral therapy (CBT), as an adjunct to outpatient treatment that includes transmucosal buprenorphine and contingency management, for patients 18 years or older who are currently under the supervision of a clinician.
For a brief summary of prescribing information on reSET or reSET-O please see links below:
Headquartered in Wilmington, Delaware, ChristianaCare is one of the country’s most dynamic health care organizations, centered on improving health outcomes, making high-quality care more accessible and lowering health care costs. ChristianaCare includes an extensive network of primary care and outpatient services, home health care, urgent care centers, three hospitals (1,299 beds), a free-standing emergency department, a Level I trauma center and a Level III neonatal intensive care unit, a comprehensive stroke center and regional centers of excellence in heart and vascular care, cancer care and women’s health. It also includes the pioneering Gene Editing Institute and was rated by IDG Computerworld as one of the nation’s Best Places to Work in IT. ChristianaCare is a nonprofit teaching health system with more than 260 residents and fellows. With the unique CareVio data-powered care coordination service and a focus on population health and value-based care, ChristianaCare is shaping the future of health care. Learn how ChristianaCare delivers greater quality and value at https://christianacare.org.
About Pear Therapeutics
Pear Therapeutics is the leader in prescription digital therapeutics, or PDTs, and aims to redefine medicine by discovering, developing, and delivering clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from FDA. The organizations lead product, reSET®, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from FDA to treat disease. Pear’s second product, reSET-O®, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear’s third product, Somryst™ for the treatment of chronic insomnia, was the first PDT submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program. For more information, visit Pear at www.peartherapeutics.com.